News | July 17, 2024
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
The Government of India continues to prioritise initiatives aimed at enhancing the accessibility and equity of health services
The biopharmaceutical leader shared its expert perspective at the Equality Lounge at the G20 Summit
These initiatives aim to improve access to healthcare for rare disease patients
Subscribe To Our Newsletter & Stay Updated
